海曲泊帕联合重组人血小板生成素治疗抗肿瘤治疗所致血小板减少症的回顾性队列研究  

A retrospective cohort study of hetrombopag combined with recombinant human thrombopoietin in the treatment of thrombocytopenia due to antineoplastic therapy

作　　者：杨婧[1] 严冬 仝营营 高芸菲[1] 王凯 张旭阳 樊聪 王莉[1] 孔曼[1] YANG Jing;YAN Dong;TONG Yingying;GAO Yunfei;WANG Kai;ZHANG Xuyang;FAN Cong;WANG Li;KONG Man(Beijing Luhe Hospital,Capital Medical University,Beijing,101100,China)

机构地区：[1]首都医科大学附属北京潞河医院肿瘤中心,北京101100

出　　处：《临床血液学杂志》2024年第11期794-798,共5页Journal of Clinical Hematology

基　　金：国家自然科学基金(No:82203576)。

摘　　要：目的回顾性分析TPO受体激动剂(TPO-RA)+重组人血小板生成素(rhTPO)联合给药与rhTPO单药治疗肿瘤治疗所致血小板减少症(cancer therapy induced thrombocytopenia,CTIT)的有效性和安全性,探索联合给药的临床益处,为CTIT患者带来新的治疗选择。方法回顾性分析应用海曲泊帕联合rhTPO与rhTPO单药治疗CTIT患者的临床资料。主要研究终点为7 d内治疗应答比例。结果本研究共纳入58例符合纳入与排除标准的CTIT患者,其中海曲泊帕+rhTPO联合组28例,rhTPO单药组30例。海曲泊帕+rhTPO联合组7 d内治疗应答比例为75%(21/28),rhTPO单药组为30%(9/30),差异有统计学意义(P<0.05)。海曲泊帕+rhTPO联合组中位治疗天数为6.5 d,rhTPO单药组中位治疗天数为9.5 d,差异有统计学意义(P<0.05)。结论研究表明海曲泊帕联合rhTPO给药可能为3/4级血小板减少症患者提供一种新的治疗选择,可以更快、更有效地提高血小板水平,且安全性良好。Objective To retrospectively analyze the effectiveness and safety of TPO-RA in combination with rhTPO vs rhTPO alone,and to explore the benefits of the combination therapy in order to bring new treatment options for patients with cancer therapy induced thrombocytopenia(CTIT).Methods The clinical data of CTIT patients who received hetrombopag in combination with rhTPO vs.rhTPO alone were retrospectively analyzed.The primary outcome was the proportion of treatment response within 7 days.Results A total of 58 patients with CTIT who met the case screening criteria were included in this study,including 28 patients in the hetrombopag+rhTPO group and 30 patients in the rhTPO alone group.The proportion of treatment response within 7 days was 75%(21/28)in the hetrombopag+rhTPO group and 30%(9/30)in the rhTPO monotherapy group.There were significant difference between the two groups(P<0.05).The median treatment duration were 6.5 days in the hetrombopag+rhTPO group and 9.5 days in the rhTPO monotherapy group.There were significant difference between the two groups(P<0.05).Conclusion This retrospective study suggests that hetrombopag combined with rhTPO may be a treatment option for patients with grade 3/4 thrombocytopenia by providing a faster and more effective boost in platelet levels without increasing safety concerns.

关 键 词：海曲泊帕 重组人血小板生成素 肿瘤治疗所致血小板减少症 血小板生成素 

分 类 号：R558[医药卫生—血液循环系统疾病]